Drug Overview
Plavix (clopidogrel; Sanofi/Bristol-Myers Squibb) is an antiplatelet agent that inhibits blood clot formation.
It works by irreversibly binding to the blood platelet’s adenosine diphosphate (ADP) P2Y12 receptor, preventing ADP-mediated activation of the glycoprotein IIb/IIIa complex.
By preventing the activation of this complex, Plavix prevents platelet aggregation from occurring, and prevents the formation of blood clots.
Plavix (clopidogrel; Sanofi/Bristol-Myers Squibb) is an antiplatelet agent that inhibits blood clot formation.
It works by irreversibly binding to the blood platelet’s adenosine diphosphate (ADP) P2Y12 receptor, preventing ADP-mediated activation of the glycoprotein IIb/IIIa complex.
By preventing the activation of this complex, Plavix prevents platelet aggregation from occurring, and prevents the formation of blood clots.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Plavix: Stroke
Plavix: Acute coronary syndrome
LIST OF FIGURES
Figure 1: Plavix for ischemic stroke – SWOT analysis
Figure 2: The authors drug assessment summary of Plavix for ischemic stroke
Figure 3: The authors drug assessment summary of Plavix for ischemic stroke
Figure 4: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
Figure 5: Plavix for acute coronary syndrome – SWOT analysis
Figure 6: The authors drug assessment summary for Plavix in acute coronary syndrome
Figure 7: The authors drug assessment summary for Plavix in acute coronary syndrome
LIST OF TABLES
Table 1: Plavix drug profile
Table 2: Plavix pivotal trial data in ischemic stroke
Table 3: Plavix ongoing late-phase clinical trials in ischemic stroke
Table 4: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
Table 5: Plavix drug profile
Table 6: Plavix pivotal trial data in acute coronary syndrome
